News | May 04, 2024
Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Sales reflect continued strong growth in oncology and vaccines
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Subscribe To Our Newsletter & Stay Updated
